Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer: the ESTANVO Randomized Trial

NCT06817161 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT06817161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06817161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer: the ESTANVO Randomized Trial
Lead sponsor
Centre Francois Baclesse
Phase
Phase 3
Overall status
Recruiting
Start date
April 30, 2025
Completion date
September 30, 2028
Enrollment
116 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

digestive system disorders, first line chemotherapy, ovarian carcinoma